Neuropathy Device Maker Files

7510

By: Diabetes Health Staff

NeuroMetrix, Inc., a Massachusetts-based medical device company, has filed a 510(k) form with the US Food and Drug Administration for the SENSUSTM, a pain therapy device for people who suffer diabetic neuropathy. A 510(k) is a “premarket notification” of a company’s intent to market a medical product. The FDA then tests the product and provides feedback to the manufacturer. Once the FDA clears the product, its maker can introduce it to the US market.

SENSUS is a “transcutaneous electrical nerve stimulation” device that works by sending low-voltage currents to nerves through electrodes attached to the skin. In diabetic neuropathy, nerves become inflamed and damaged over time from high blood sugar levels. Studies have shown that many people afflicted with neuropathy enjoy relief from pain when affected nerves receive electric stimulation.

Up to 20 percent of people with diabetes suffer from diabetic neuropathy. If the condition is advanced, they can experience extreme pain and loss of mobility. Physicians usually treat the condition with drugs, which have varying degrees of effectiveness. NeuroMetrix says that eventual FDA approval of SENSUS will make available another mode of pain management.

Comments

comments

Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.